# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Moderna cuts its 2024 sales forecast due to weaker demand for COVID-19 vaccines. Sales now expected between $3B-$3.5B, down fro...
- Reuters
Tech stocks soared to their best session in five months on Wednesday, ahead of the highly anticipated Federal Open Market Commi...
GSK reported Q2 sales of $9.95 billion, beating estimates of $9.66 billion. Specialty Medicine sales rose 20%, driven by strong...
Tech optimism is likely to abound on Wall Street as AI-levered stocks are feeding off the strength generated by Advanced Micro ...
GSK plc (NYSE:GSK) and Flagship Pioneering (Flagship), the bioplatform innovation company, today announced they have entered a ...
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say followin...